Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Kiniksa Pharmaceuticals Ltd. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is being handled by 1 distinct examiner within 1 distinct art unit. Such a concentrated prosecution profile indicates that the company's current interactions with the patent office are focused on a specific technical niche or a single high-priority application.
RUIXIANG LI is the busiest examiner for this portfolio, currently managing 1 busiest examiner pending action. Because this individual is the only examiner assigned to the company's pending work, the immediate success of the prosecution strategy depends entirely on the dialogue with this specific official. The presence of only 1 distinct art unit further suggests a narrow jurisdictional focus for the pending Biotechnology & Pharmaceuticals claims.
With 1 pending office action in total, the administrative burden on the legal team is currently limited to a single response cycle. This allows for a highly specialized approach to the examiner's requirements. The data shows no distribution of work across other units, reinforcing the singular nature of the current patent office engagement.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LI, RUIXIANG | 1 | 59.5% | +18.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18672896 | STABLE ANTI-OSMR ANTIBODY FORMULATION | LI, RUIXIANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18672896 | STABLE ANTI-OSMR ANTIBODY FORMULATION | LI, RUIXIANG | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18672896 | STABLE ANTI-OSMR ANTIBODY FORMULATION | LI, RUIXIANG | 1674 | §102§103§112Other | Non-Final OA | — | Pending | May 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKiniksa Pharmaceuticals Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ruixiang Li has the most, with 1 of Kiniksa Pharmaceuticals Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
